Form 4: Travere Therapeutics Insider Sells Shares
Statement of Changes in Beneficial Ownership
Elizabeth E. Reed, Chief Legal Officer of Travere Therapeutics, sold 10,000 shares of common stock on April 1, 2026, as part of a pre-arranged 10b5-1 trading plan.
Summary
- Elizabeth E. Reed, Chief Legal Officer and General Counsel at Travere Therapeutics, Inc., reported a transaction involving company stock.
- On April 1, 2026, Ms. Reed sold 10,000 shares of common stock at a price of $15.46 per share.
- This sale was executed as part of a written trading plan adopted on June 16, 2025, which is intended to comply with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
- The shares sold were part of a stock option grant received by Ms. Reed on January 31, 2020, which was fully vested and exercisable.
- Following this transaction, Ms. Reed beneficially owns 105,211 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing neutrally, as it reports a standard insider stock sale executed under a pre-arranged 10b5-1 plan, which mitigates concerns about insider trading based on material non-public information.
Negatives
- Insider selling of company stock can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established trading plan.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it solely reports a past transaction.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a 10b5-1 plan indicates a structured approach to stock sales, often used by executives to diversify holdings or manage personal finances without implying negative sentiment about the company's prospects.
Stakeholder Impact
- Shareholders: The sale is conducted under a pre-arranged plan, which is designed to avoid the appearance of trading on material non-public information. However, any insider selling can be a point of observation for investors.
Key Dates
| Date | Description |
|---|---|
| 01/31/2020 | Date of stock option grant to Reporting Person. |
| 06/16/2025 | Date written trading plan adopted. |
| 04/01/2026 | Transaction Date (Sale of common stock and exercise of stock option). |
| 04/02/2026 | Date of signature on the filing. |
Keywords
Form 4, Insider Trading, Travere Therapeutics, TVTX, Stock Option, 10b5-1 Plan, Securities Exchange Act, Beneficial Ownership, Common Stock, Elizabeth E. Reed
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.